Yes, exposure to mold can trigger conjunctivitis. Specifically, mold is an environmental trigger that can result in allergic conjunctivitis. As the name suggests, this is a type of conjunctivitis ...

No, you should avoid wearing eye makeup if you have conjunctivitis, also known as pink eye, until the infection clears. While makeup is not usually the cause of your infection or irritation ...

Dupixent (dupilumab) is a brand-name injection that’s prescribed for treating asthma. This article covers topics such as side effects, dosage, and how Dupixent works. Dupixent is available as a ...

One primary reason is the strong performance and potential of Dupixent, which is expected to partially counterbalance the uncertainties surrounding Eylea. The expected growth in Dupixent’s ...

Among other topics, Hudson discussed the success of Dupixent (dupilumab), highlighting that it has reached over $13bn in global sales, which affirms its commercial advantage and sets a milestone ...

Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications for the ...

This makes the new indication for Dupixent very important for Sanofi as it searches for a blockbuster to transform its fortunes. The FDA is set to make a decision on Dupixent’s new indication on ...

Furthermore, the successful launch of Dupixent for chronic obstructive pulmonary disease (COPD) has garnered significant coverage from top commercial and Medicare payers, indicating strong market ...

Sanofi’s super autoimmune blockbuster Dupixent helped drive an 11.3% sales increase in 2024, a result touted by executives as a win but one analyst called a slight miss. In full-year earnings results ...

The use of Sanofi’s Dupixent in atopic dermatitis has set a high benchmark for competitors within the space. Credit: marishkaSm via Shutterstock. Sanofi’s participation at the JP Morgan 43rd Annual ...

Sanofi’s chief executive Paul Hudson discussed the success of Dupixent (dupilumab)and the remarkable achievement of over $13 billion in global sales in 2024, highlighting its commercial advantage and ...

Figure 2. Distribution of time to occurrence of serious ADRs. Among the ADRs outcomes, 10 cases (15.38%) showed improvement (including 2 cases of allergic conjunctivitis, 4 cases of conjunctivitis, 3 ...